ERLIN2

Across TCGA pan-cancer cohorts, ERLIN2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ERLIN2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ERLIN2 RNA is repressed in tumor relative to normal tissue. In most cancer types ERLIN2 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and LUSC are the cancer types where ERLIN2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERLIN2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.171	<.001	10	view →
KIRC	Male	II,III,IV	−0.521	<.001	9	view →
LUSC	All	II,III,IV	+0.897	<.001	7	view →
KICH	Male	All	−1.091	<.001	6	view →
CHOL	All	II,III,IV	+1.290	.011	4	view →
STAD	All	All	+0.529	.001	4	view →
HNSC	All	All	+0.448	.005	4	view →
BLCA	Female	III,IV	+0.758	.015	3	view →
UCEC	All	All	−0.439	.040	2	view →
READ	Female	All	−0.429	.018	2	view →
LUAD	All	All	+0.260	.022	2	view →
KIRP	All	All	−0.254	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ERLIN2–THCA

Open the THCA breakdown →